Andrew Left’s tumultuous journey through the stock market over the past decade has been marked by significant highs and lows. Known as a formidable short-seller, he gained prominence as the founder of Citron Research, particularly for his critical reports on Valeant Pharmaceuticals in 2015, where he described the company as the “pharmaceutical Enron.” His insights were pivotal in bringing to light fraudulent practices at Valeant, earning him a reputation that caused stocks to react swiftly to his analyses.
However, the tides turned during the GameStop phenomenon in 2021. Caught short amid a 2,000% rally, Left’s public standing began to falter, prompting him to cease publishing short-seller research. Adding to his challenges, the Securities and Exchange Commission (SEC) charged him with market manipulation and securities fraud in July 2024, with his trial set to commence in March 2026.
Despite these setbacks, Left recently demonstrated moments of his earlier prowess. On August 14, he appeared on Fox Business and declared Palantir, a stock that had surged 144% that year, to be overvalued. “I’ve stopped even looking at the ratio because it’s become so absurd,” he asserted regarding the company’s price-to-earnings ratio. His critique seemed to resonate, as Palantir’s stock subsequently fell 17% in the weeks that followed.
In a recent conversation with Business Insider, Left clarified that while he remains confident in his analysis skills, he is now focusing on long-term investments rather than short-selling. He cited interest in a private AI company, Databricks, which is currently one of the largest unicorns. He explained that his skepticism towards Palantir is not indicative of its overall performance but rather its inflated valuation. Left praised Palantir’s CEO, Alex Karp, while asserting that Databricks presents a more favorable investment opportunity.
“There’s no denying that most would agree Databricks is the stronger business today,” he remarked, acknowledging the company’s robust growth trajectory and strong fundamentals. In a recent post on X for Citron Research, he highlighted how Databricks recently achieved a $100 billion valuation, suggesting Palantir would need to be valued similarly for its stock to align with expectations—placing Palantir shares at approximately $40, a dramatic drop from its current valuation.
The investment landscape surrounding Databricks appears promising, yet potential investors may need to exercise patience, as the company has indicated it has no immediate plans for an IPO. Current assessments suggest only a 10% likelihood of an announcement this year, down from 30% previously, emphasizing the need for strategic foresight in this volatile market.
